是否需更改托吡酯治疗参考范围?
该研究基于挪威常规治疗药物监测数据,评估托吡酯血药浓度与临床结局的关系。分析1721份ADR样本和294份单药治疗样本,发现5-20 mg/L范围内儿童癫痫控制更佳,且ADR与血药浓度无关,结论为不建议更改治疗参考范围。
要点
- 儿童血药浓度5-20 mg/L较<5 mg/L癫痫控制更优。
- 无癫痫发作患者与有发作患者血药浓度无差异。
- 不良反应报告率2.8%,与血药浓度无关。
核心结论
- 不建议更改托吡酯的治疗参考范围。
研究设计与样本
- 基于常规治疗药物监测申请单的回顾性研究,评估1721份谷浓度样本的浓度依赖性不良反应,并对294份单药治疗样本进行癫痫频率分析。
主要发现
- 儿童整体队列无癫痫发作比例49% vs 成人37%,单药治疗中儿童56% vs 成人44%。
- 儿童血药浓度5-20 mg/L vs <5 mg/L无发作比例65% vs 44%。
- 儿童血药浓度5-10 mg/L vs <2 mg/L无发作比例63% vs 14%。
- 无癫痫发作患者与有发作患者血药浓度无差异。
- 2003-2005年癫痫控制较2006-2011年差;38份样本(2.8%)报告不良反应,与血药浓度无关。
临床怎么用
- 临床解读托吡酯血药浓度时,可继续参考5-20 mg/L范围,尤其关注儿童癫痫控制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: The Norwegian Association for Clinical Pharmacology in their National Guidelines decreased the therapeutic range (TR) of topiramate (TPM) from 5-20 mg/L to 2-10 mg/L. The objective of this study is to ascertain which TR produces better clinical outcomes. METHODS: The data sources were request forms for routine therapeutic drug monitoring (TDM) of TPM. Concentration dependent adverse drug reactions (ADRs) were evaluated in 1721 samples taken pre-dose. Seizure frequency analysis was performed in 294 samples of monotherapy. Statistical analysis was performed using Prism 5.0, GraphPad Instatt: One-way ANOVA with Bonferroni correction for median plasma level (PL) and χ2 -test with Bonferroni correction for seizure frequency and for distribution of PL according to TR 5-20 mg/L and intervals <2, 2-5, 5-10, 10-20, >20 mg/L. RESULTS: Better seizure control was found in children both in the whole cohort (without seizure 49% vs 37% adults), as well as in monotherapy (56% vs 44%), in children with PL 5-20 mg/L vs <5 mg/L (65% vs 44%) and in children with PL 5-10 mg/L vs <2 mg/L (63 vs 14%). PL in seizure-free patients did not differ from those with seizure. Seizure control was poorer in the period 2003-2005 compared to 2006-2011. ADRs reported in 38 samples (2.8%) were not related to PL. CONCLUSIONS: Change of TR is not recommended.
引用
- Koristkova B, Grundmann M, Brozmanova H, et al. Was it necessary to change the therapeutic range of topiramate? Br J Clin Pharmacol. 2021. PMID: 34265104. doi:10.1111/bcp.14985
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。